May 10, 2017
BMS and Calithera Biosciences expend collaboration to test its cancer drugs
Bristol-Myers Squibb (BMS) and Calithera Biosciences have expanded their existing collaboration to evaluate BMS’s Opdivo in combination with Calithera’s CB-839 in patients with non-small cell lung cancer (NSCLC) and melanoma.
